Koers InMed Pharmaceuticals Inc. Toronto S.E.
Aandelen
IN
CA4576376012
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 7,3 mln. 5,33 mln. 4,99 mln. | Omzet 2025 * | 9,12 mln. 6,67 mln. 6,24 mln. | Marktkapitalisatie | 1,91 mln. 1,39 mln. 1,3 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 0,26 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,21 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | 13 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,64% |
Recentste transcriptie over InMed Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-16 |
Chief Operating Officer | - | 05-11-18 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11-02-22 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-16 |
Andrew Hull
CHM | Chairman | 61 | 12-09-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |